Myriad Genetics, Inc. (MYGN) has a consensus analyst rating of Hold, based on 36 analysts covering the stock. Of those, 8 recommend buying, 22 recommend holding, and 6 recommend selling.
The analyst consensus price target for MYGN is $6.00, representing a +22.2% upside from the current price of $4.91. Price targets range from a low of $6.00 to a high of $6.00.
